Abstract. Prostate cancer cells exist under hypoxic conditions. Hypoxia has a detrimental effect on the efficacy of treatment and final outcome in patients with prostate cancer. There have been a large number of endogenous markers of hypoxia described previously across a range of cancer types, both in vitro and in vivo. The aim of this study was to evaluate the expression of a range of hypoxia-associated genes within benign prostatic hypertrophy (BPH) and prostate cancer tissue. Messenger RNA was extracted from primary prostate tissue obtained from 67 men with benign prostatic hypertrophy or prostate cancer (Gleason score 5 to 10). Real-time polymerase chain reaction was performed to quantify the expression levels of 12 hypoxia-associated genes in these tissues. Expression of lysyl oxidase (LOX) and glucose transporter-1 (GLUT-1) genes were significantly higher in prostate cancer compared with BPH tissue (P<0.05) and correlated with Gleason score (LOX: R=0.297, P=0.015; GLUT-1: R=0.274, P=0.026). HIF-2α had a negative correlation with Gleason score (R=-0.309, P=0.012). The remaining hypoxia-associated genes did not show any specific pattern of expression in prostate tissue. Numerous molecules have been proposed as endogenous markers of hypoxia. The findings of this study illustrate that not all hypoxia-associated molecules are relevant to prostate cancer in vivo. However, LOX and GLUT-1 are candidate markers of hypoxia in prostate cancer and may prove useful in identifying patients with hypoxic prostate cancer. Not all hypoxia-associated molecules are relevant in prostate cancer in vivo.
Introduction
It is well established that solid tumours >1 cm 3 , including prostate cancer, exist under fluctuating oxygen tensions and are exposed to both acute and chronic hypoxia (1, 2) . The presence of a hypoxic cancer microenvironment correlates with increased tumour invasiveness, metastases and resistance to radio-and chemotherapy (3) (4) (5) (6) . Furthermore, hypoxia is an independent prognostic indicator of poor clinical outcome for patients with prostate and other cancers (5, 7) . Numerous genes and proteins have been demonstrated to be upregulated under hypoxic conditions in a range of tumours. However, none of the various exogenous and endogenous markers of hypoxia described previously has emerged as the goldstandard method of identifying tumour hypoxia (1) . A mechanism of reliably and easily identifying the oxygen status of a man's prostate cancer would be very useful in individualising treatment, especially with respect to the timing of radiotherapy.
Existing exogenous methods of measuring oxygen levels in a nidus of prostate cancer (e.g. Eppendorf probe, nitroimidazole agents) give heterogeneous results and do not correlate with each other or clinical outcome (1) . As such, the aim of this study was to study the expression by benign prostatic hypertrophy (BPH) and prostate cancer tissue of a range of biological markers purported to be produced by tumour cells in response to hypoxia. We aimed to determine how expression of hypoxia-associated genes correlated with pathology and identify if any of the genes showed promise for use within a panel of markers for the identification of hypoxic prostate cancer. RNA extraction. Total RNA from the prostate tissues was isolated by first homogenising tissues in RNAzol (Biogenesis, Poole, UK) and then by using the Promega SV Total RNA Isolation System (Promega Corporation, USA) to remove DNA and purify the RNA. RNA was re-suspended in nuclease free water and concentrations determined using a Nanodrop spectrophotometer (LabTech International, Ringmoor, UK).
Quantitative real-time PCR. cDNA preparation and real-time PCR were performed as previously described (9, 10) . Briefly, 1 μg of total RNA was reverse transcribed using 2 μg random hexamers (Amersham) and Superscript II reverse transcriptase (Life Technologies, Paisley, UK) according to the supplier's instructions. cDNA was stored at -20˚C until used in the PCR. Relative expression levels were quantified for the following hypoxia-associated genes: vascular endothelial growth factor A (VEGF-A), prolyl hydroxylase 2 (PHD2), inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), carbonic anhydrase IX (CAIX), lysyl oxidase (LOX), hypoxia inducible factor-1α (HIF-1α), hypoxia inducible factor-2α (HIF-2α), glucose transporter-1 (GLUT-1), erythropoietin (EPO), E-cadherin, angiopoietin-2 (Ang2). Gene-specific primers were designed to span Universal Probes using Roche Applied Science (Burgess Hill, UK) Universal Probe Library Assay Design Centre. Universal probe identities are listed in Table I . Primers were synthesised by Sigma Genosys (Gillingham, UK) sequences for all primers and universal probe identities are given in Table I . VEGF-A primers and probes were preexisting and designed using Primer Express 1.0 software (Applied Biosystems, Warrington, UK) and synthesised by Applied Biosystems. All primers spanned exon boundaries. BLASTN searches were conducted on all primer/probe nucleotide sequences to ensure gene specificity. The 18S ribosomal RNA (18S rRNA) gene was used as an endogenous control to normalise for differences in the amount of total RNA in each sample, using previously validated procedures (9, 11) ; 18S rRNA primers and probe were purchased from Applied Biosystems. PCR reactions were performed using the ABI Prism 7500 Fast Sequence Detection System (Applied Table I . Primer sequences of the genes analysed by quantitative RT-PCR. 
Sequences for the primers are shown in the 5' to 3' orientation.
- To determine the relative RNA levels within the samples, standard curves for the PCR reaction were prepared by using the cDNA from one sample and making 2-fold serial dilutions covering the range equivalent to 20-0.625 ng of RNA (for 18S rRNA analyses, the range was 4-0.125 ng). Additionally, the median C T values of the genes analysed were used to classify expression as: very high (C T <25.5), high (≥25.5 C T <30.5), moderate (≥30.5 C T <35.5), low/absent (≥35.5 C T <40), or not detected/below the limits of detection (C T = 40) (9) . Because of a drop off in sensitivity of the instrument, C T values ≥35.5 are unreliable, in terms of exact levels of mRNA expression.
Statistical analysis. The data did not satisfy normality or equal variance, so nonparametric tests were used. The Mann-Whitney U test was carried out to compare prostate cancer and BPH samples. Further tests were carried out using the two-tailed Spearman rank correlation coefficient to determine whether there were associations with the Gleason sum score. The results were analysed using SPSS (version 13.0; SPSS Inc. Headquarters, Chicago, IL, USA), P<0.05 was regarded as significant.
Results
Comparison of hypoxia-associated gene expression by BPH and prostate cancer. Of the 12 hypoxia-associated genes quantified using real-time PCR two, LOX ( Fig. 1a; P=0 .047) and GLUT-1 ( Fig. 1b; P=0 .03), demonstrated a significant difference between prostate cancer and BPH mRNA samples (Table II) . Furthermore, a correlation existed between increasing Gleason score and increasing expression levels of both LOX (R=0.297, P=0.015) and GLUT-1 (R=0.274, P=0.026) ( Table II , Fig. 1 ).
None of the other 10 hypoxia-associated genes examined correlated with Gleason score, other than HIF-2α which demonstrated a negative correlation with Gleason score (R=-0.309, P=0.012; Table II and Fig. 2 ). However, there was not a significant difference in HIF-2α expression between BPH and prostate cancer mRNA samples.
Absolute expression levels of hypoxia-associated genes.
Table II details the median C T values of BPH and prostate cancer samples for each hypoxia-associated gene assessed. Using the arbitrary grouping of expression levels outlined in the methods section all hypoxia-associated genes had moderate, high or very high levels of expression. The C T values for BPH and cancer samples for the following genes: COX-2, Ang2 and HIF-2α were in different 'level of expression' groups. However, as there was no significant difference between the BPH and prostate cancer mRNA expression levels for any of these genes this variation in categorisation does not represent a real difference between the samples. E-cadherin, VEGF-A and HIF-1α had very high levels of expression in both BPH and prostate cancer samples. EPO, CAIX and iNOS had moderate levels of mRNA expression in both BPH and prostate cancer. The remaining genes all had high levels of expression.
Correlations between individual hypoxia-associated genes.
There were a variety of correlations between individual hypoxia-associated genes. However, as LOX and GLUT-1 were the only 2 genes to demonstrate a significant difference between BPH and prostate cancer samples correlation between other genes were not meaningful.
Discussion
It is well established that prostate cancer cells are found under hypoxic conditions in vivo. However, there has been no evaluation of the expression of hypoxia-associated genes in primary prostate tissue. This study assessed the mRNA expression of hypoxia-associated molecules in BPH and prostate cancer tissue. Of the hypoxia-associated genes assessed, expression of LOX and GLUT-1 were significantly higher in prostate cancer than BPH tissue and correlated with Gleason score. Although many endogenous markers have been Table II . NM, non-malignant. associated with the hypoxia response in cancers they are not all necessarily upregulated in primary prostate cancer tissue.
Strengths of this study were the use of RNA from primary prostate samples of 67 men with both BPH and prostate cancer and the representation of a range of Gleason scores by the specimens from which mRNA was extracted. However, we recognise the limitations of this study. Firstly, there were no matched protein samples from the same patients donating samples for RNA extraction. Matched patient samples would have strengthened the analysis by allowing validation of the genes upregulated at the RNA level and direct comparison of gene and protein expression. Secondly, there was incomplete data regarding endocrine therapy or radiotherapy given to patients in this study which may have altered the oxygen status and potentially the hypoxic proteome (12) . Lastly, although several hundred hypoxia-associated molecules have been identified, only a few common molecules were chosen for analysis in this study.
Approximately 1-1.5% of the genome is transcriptionally responsive to hypoxia, although this varies between different cell types (13) . All of the genes studied in this study have previously been demonstrated to be upregulated by hypoxia in vitro and/or in vivo tumour models, resulting in a more aggressive, treatment-resistant phenotype (14) (15) (16) (17) . Furthermore, a recent study from Vergis and co-workers demonstrated that two of the molecules assessed in the present study, HIF-1α and VEGF, identified patients with localised prostate cancer at high risk of biochemical failure (18) . However, few of the hypoxia-associated genes analysed in this study revealed major differences between BPH and prostate cancer at the transcriptional level.
Two of the 12 genes assessed, LOX and GLUT-1, were significantly upregulated in prostate cancer tissue compared with benign prostate tissue. Furthermore, LOX and GLUT-1 expression correlated with Gleason score. Both LOX and GLUT-1 have previously been reported as hypoxia-associated genes involved in metastasis and glucose transport respectively (14, 19) . Hypoxic cancer cells overexpress GLUT-1 to accelerate glucose intake mainly for low effective, anaerobic respiration, preventing death due to oxygen deficiency (20) . LOX is an extracellular matrix protein that is consistently overexpressed by hypoxic human tumour cells (13) and is also a useful marker of the hypoxia response in vitro (21) . Further studies at the protein level are needed to confirm if LOX and GLUT-1 will form useful hypoxia markers in prostate cancer. However, in other unpublished studies from our laboratory we have failed to find a reliable antibody against LOX for immunoblotting or immunohistochemistry.
Expression of COX-2 and iNOS are known to increase with increasing grade/stage of prostate cancer (22, 23) . In the present study, neither COX-2 nor iNOS showed a significant upregulation of mRNA expression in prostate cancer vs. BPH samples. Although COX2 and iNOS have previously been associated with the hypoxia response of tumours (15) (16) (17) , the varying known regulatory factors controlling expression of COX-2 and iNOS implies that it is unclear if hypoxia, or different factor(s), were regulating expression in prostate cancer.
HIF-1 is a heterodimeric transcription factor which is the prototypical hypoxia-associated molecule (24) . HIF-1α is the master regulator of the hypoxia response, causing upregulation of effector genes by binding to the hypoxia response element within their promoter regions. HIF-1α protein staining has been shown to be greater in prostate cancer than BPH tissue and to identify patients at high risk of biochemical failure (18, 25) . As such, HIF-1α mRNA levels would intuitively be expected to be increased as grade of cancer increased. In the current study there was a trend for higher HIF-1α mRNA expression in prostate cancer vs. BPH samples but this was not statistically significant. However, this finding agrees with previous studies showing that HIF-1α is regulated at the post-translational rather than transcriptional level (26). 
Alternatively, the lack of the expected pattern of HIF-1α mRNA expression may be due to the time lag between biopsy and freezing of biopsy sample following biopsy/surgery. Since, when HeLa cells were incubated at 1% oxygen for 4 h and then returned to 21% oxygen, HIF-lα RNA decreased to below basal levels within 5 min and HIF-1α protein within 15 min (27) . Such difficulties suggest that HIF-1α mRNA (and perhaps protein) levels cannot be used as a reliable, routine marker for hypoxia or advanced disease in prostate cancer. Furthermore, these same issues may influence the expression of other hypoxia-associated molecules.
Whereas previous studies have demonstrated HIF-2α immunohistochemical staining correlated with HIF-1α in prostate neoplastic tissue (i.e. increased in neoplasia compared with benign tissue) (28) , in the present study HIF-2α mRNA showed a negative correlation with Gleason score. However, there was no significant difference between HIF-2α in BPH and prostate cancer tissue. Further evaluation of HIF-2α protein levels must be made before conclusions can be made about this potential contradiction between HIF-2α mRNA and protein levels.
Many of the genes evaluated in this study have been identified as potential markers of hypoxia in vitro, in vivo and across different tumour types (1) . For example CAIX is a good marker of hypoxia in immortalised prostate cancer cells i.e. showing reliable increases in mRNA expression following hypoxia incubation of PC-3 cells as measured by real-time PCR (21) . Furthermore, the results of the present study revealed moderate expression levels of CAIX by both BPH and prostate cancer tissue. However, no significant difference in CAIX mRNA expression was found between BPH and prostate cancer tissue. These results are discordant with previous findings that CAIX is not expressed by primary prostate cancer (29) .
The association established in this study of LOX and GLUT-1 with prostate cancer and increasing Gleason score may be independent of oxygen tension and simply a factor of worsening pathology. It has been established that factors other than hypoxia can modulate hypoxia-associated gene expression levels. For example, previous studies showed that HIF-1α expression could be reduced in peri-necrotic tumour by insufficient nutrients (30) ; similarly, a number of hypoxiaassociated genes can be upregulated by perturbations in pH (31). This study did not include any direct methods of measuring hypoxia to correlate with endogenous marker expression. Future studies must assess hypoxia-associated molecules expressed in primary cancer tissue and link expression with intratumoural oxygen levels. However, tumour hypoxia is cyclical having a mix of acute and chronic hypoxia and a constantly changing environment due to a perpetually altering microvascular supply (1). Ultimately, a dynamic method of measuring tumour hypoxia, rather than static measurement of endogenous markers, may be the only way of allowing the tailored treatment of hypoxic prostate cancer, e.g. identify the optimal time to deliver radiotherapy to a man with prostate cancer.
Although the majority of the hypoxia-associated genes analysed in this study were expressed at high levels in prostate tissue most did not show any difference between BPH and cancer or have any correlation with pathological grade. Previous reviews have suggested that rather than considering individual genes a panel of genes may provide a more accurate reflection of the hypoxic state of a tumour (1) . From the present study GLUT-1 and LOX would be suitable genes to include in a hypoxia panel.
